FLT3-话题@MedSci

#FLT3#

40篇内容 | 818人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1538907, encodeId=61db153890e24, content=<a href='/topic/show?id=5f04e51467' target=_blank style='color:#2F92EE;'>#FLT3#</a>, objectTitle=Blood：Gilteritinib联合阿扎胞苷 vs 单用阿扎胞苷治疗新诊断的FLT3mut+AML, objectType=article, longId=735575, objectId=dcf5e35575d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dcf5e35575d5, replyNumber=0, likeNumber=44, createdTime=2022-08-12, rootId=0, userName=fengyi816, userId=57a713069145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dcf5e35575d5, moduleTitle=Blood：Gilteritinib联合阿扎胞苷 vs 单用阿扎胞苷治疗新诊断的FLT3mut+AML, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dcf5e35575d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538906, encodeId=7bf01538906f8, content=<a href='/topic/show?id=5f04e51467' target=_blank style='color:#2F92EE;'>#FLT3#</a>, objectTitle=《BLOOD》吉瑞替尼联合阿扎胞苷治疗不适合强化疗的初治FLT3突变AML的3期研究结果, objectType=article, longId=735420, objectId=695de35420b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=695de35420b3, replyNumber=0, likeNumber=47, createdTime=2022-08-11, rootId=0, userName=fengyi816, userId=57a713069145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=695de35420b3, moduleTitle=《BLOOD》吉瑞替尼联合阿扎胞苷治疗不适合强化疗的初治FLT3突变AML的3期研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=695de35420b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538905, encodeId=880815389055c, content=<a href='/topic/show?id=5f04e51467' target=_blank style='color:#2F92EE;'>#FLT3#</a>, objectTitle=J Clin Oncol：维奈托克联合吉特替尼治疗FLT3突变型急性髓系白血病, objectType=article, longId=734106, objectId=f1c8e341064d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1c8e341064d, replyNumber=0, likeNumber=43, createdTime=2022-08-03, rootId=0, userName=fengyi816, userId=57a713069145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1c8e341064d, moduleTitle=J Clin Oncol：维奈托克联合吉特替尼治疗FLT3突变型急性髓系白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f1c8e341064d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538904, encodeId=25d515389045f, content=<a href='/topic/show?id=5f04e51467' target=_blank style='color:#2F92EE;'>#FLT3#</a>, objectTitle=Ann Hematol：吉列替尼单药治疗复发/难治性 FLT3 突变急性髓细胞白血病的真实世界研究, objectType=article, longId=730781, objectId=f847e307815e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f847e307815e, replyNumber=0, likeNumber=39, createdTime=2022-06-30, rootId=0, userName=fengyi816, userId=57a713069145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f847e307815e, moduleTitle=Ann Hematol：吉列替尼单药治疗复发/难治性 FLT3 突变急性髓细胞白血病的真实世界研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f847e307815e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538903, encodeId=2ed51538903cd, content=<a href='/topic/show?id=5f04e51467' target=_blank style='color:#2F92EE;'>#FLT3#</a>, objectTitle=J Clin Oncol：索拉非尼联合标准化疗治疗FLT3/ITD+急性髓系白血病患儿的疗效和安全性, objectType=article, longId=724175, objectId=74d6e2417552, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74d6e2417552, replyNumber=0, likeNumber=30, createdTime=2022-04-14, rootId=0, userName=fengyi816, userId=57a713069145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74d6e2417552, moduleTitle=J Clin Oncol：索拉非尼联合标准化疗治疗FLT3/ITD+急性髓系白血病患儿的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74d6e2417552)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538902, encodeId=667b153890266, content=<a href='/topic/show?id=5f04e51467' target=_blank style='color:#2F92EE;'>#FLT3#</a>, objectTitle=Blood：FLT3抑制剂Gilteritinib vs 挽救化疗对复发/难治性AML患者长期预后的影响, objectType=article, longId=299714, objectId=365f299e146f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=365f299e146f, replyNumber=0, likeNumber=37, createdTime=2022-02-28, rootId=0, userName=fengyi816, userId=57a713069145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=365f299e146f, moduleTitle=Blood：FLT3抑制剂Gilteritinib vs 挽救化疗对复发/难治性AML患者长期预后的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=365f299e146f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538901, encodeId=e50a153890117, content=<a href='/topic/show?id=5f04e51467' target=_blank style='color:#2F92EE;'>#FLT3#</a>, objectTitle=Blood：急性髓系白血病FLT3-ITD突变的克隆进化, objectType=article, longId=212621, objectId=5d5021262130, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d5021262130, replyNumber=0, likeNumber=32, createdTime=2021-06-13, rootId=0, userName=fengyi816, userId=57a713069145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d5021262130, moduleTitle=Blood：急性髓系白血病FLT3-ITD突变的克隆进化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5d5021262130)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538900, encodeId=08a915389008c, content=<a href='/topic/show?id=5f04e51467' target=_blank style='color:#2F92EE;'>#FLT3#</a>, objectTitle=Blood：靶向PRMT1介导的FLT3甲基化可增强MLL重排的ALL细胞的清除, objectType=article, longId=212557, objectId=a0ab21255e4f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a0ab21255e4f, replyNumber=0, likeNumber=39, createdTime=2021-06-12, rootId=0, userName=fengyi816, userId=57a713069145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a0ab21255e4f, moduleTitle=Blood：靶向PRMT1介导的FLT3甲基化可增强MLL重排的ALL细胞的清除, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a0ab21255e4f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538899, encodeId=85d015388994e, content=<a href='/topic/show?id=5f04e51467' target=_blank style='color:#2F92EE;'>#FLT3#</a>, objectTitle=靶向治疗新时代！吉瑞替尼成为全国最佳治疗FLT3突变型AML靶向药, objectType=article, longId=210685, objectId=fbf221068552, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fbf221068552, replyNumber=0, likeNumber=40, createdTime=2021-05-02, rootId=0, userName=fengyi816, userId=57a713069145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fbf221068552, moduleTitle=靶向治疗新时代！吉瑞替尼成为全国最佳治疗FLT3突变型AML靶向药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fbf221068552)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538898, encodeId=9199153889826, content=<a href='/topic/show?id=5f04e51467' target=_blank style='color:#2F92EE;'>#FLT3#</a>, objectTitle=Blood：糖皮质激素可增强FLT3抑制剂的抗FLT3突变型AML活性, objectType=article, longId=199165, objectId=d095199165ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d095199165ad, replyNumber=0, likeNumber=0, createdTime=2020-08-12, rootId=0, userName=fengyi816, userId=57a713069145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d095199165ad, moduleTitle=Blood：糖皮质激素可增强FLT3抑制剂的抗FLT3突变型AML活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d095199165ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538897, encodeId=b4ea153889efe, content=<a href='/topic/show?id=5f04e51467' target=_blank style='color:#2F92EE;'>#FLT3#</a>, objectTitle=FLT3抑制剂gilteritinib，获得英国NICE推荐治疗急性髓性白血病, objectType=article, longId=197734, objectId=6f8519e73405, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f8519e73405, replyNumber=0, likeNumber=32, createdTime=2020-07-20, rootId=0, userName=fengyi816, userId=57a713069145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f8519e73405, moduleTitle=FLT3抑制剂gilteritinib，获得英国NICE推荐治疗急性髓性白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6f8519e73405)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538896, encodeId=ea4f15388969b, content=<a href='/topic/show?id=5f04e51467' target=_blank style='color:#2F92EE;'>#FLT3#</a>, objectTitle=Blood：NPM1突变/MLL重排白血病患者的新希望：联合抑制Menin-MLL和FLT3, objectType=article, longId=196989, objectId=d89e19698998, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d89e19698998, replyNumber=0, likeNumber=28, createdTime=2020-07-05, rootId=0, userName=fengyi816, userId=57a713069145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d89e19698998, moduleTitle=Blood：NPM1突变/MLL重排白血病患者的新希望：联合抑制Menin-MLL和FLT3, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d89e19698998)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538895, encodeId=ee791538895db, content=<a href='/topic/show?id=5f04e51467' target=_blank style='color:#2F92EE;'>#FLT3#</a>, objectTitle=Blood：糖皮质激素增强了FLT3抑制剂的抗FLT3突变型AML活性, objectType=article, longId=195273, objectId=90381952e37a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=90381952e37a, replyNumber=0, likeNumber=22, createdTime=2020-06-05, rootId=0, userName=fengyi816, userId=57a713069145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=90381952e37a, moduleTitle=Blood：糖皮质激素增强了FLT3抑制剂的抗FLT3突变型AML活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=90381952e37a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538894, encodeId=0c6b15388948f, content=<a href='/topic/show?id=5f04e51467' target=_blank style='color:#2F92EE;'>#FLT3#</a>, objectTitle=Astellas宣布其FLT3抑制剂XOSPATA治疗白血病，正在NMPA接受监管审查, objectType=article, longId=192019, objectId=85d919201914, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85d919201914, replyNumber=0, likeNumber=37, createdTime=2020-04-13, rootId=0, userName=fengyi816, userId=57a713069145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85d919201914, moduleTitle=Astellas宣布其FLT3抑制剂XOSPATA治疗白血病，正在NMPA接受监管审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=85d919201914)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538893, encodeId=6728153889334, content=<a href='/topic/show?id=5f04e51467' target=_blank style='color:#2F92EE;'>#FLT3#</a>, objectTitle=Blood：FLT3抑制上调HDAC8使p53失活，维持FLT3-ITD+ AML细胞存活, objectType=article, longId=188122, objectId=ed321881228a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed321881228a, replyNumber=0, likeNumber=0, createdTime=2020-02-16, rootId=0, userName=fengyi816, userId=57a713069145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed321881228a, moduleTitle=Blood：FLT3抑制上调HDAC8使p53失活，维持FLT3-ITD+ AML细胞存活, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed321881228a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538892, encodeId=9659153889207, content=<a href='/topic/show?id=5f04e51467' target=_blank style='color:#2F92EE;'>#FLT3#</a>, objectTitle=Blood：NPM1/FLT3-ITD分型对AML患者预后的预测意义, objectType=article, longId=184700, objectId=54ec184e00f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=54ec184e00f7, replyNumber=0, likeNumber=0, createdTime=2019-12-14, rootId=0, userName=fengyi816, userId=57a713069145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=54ec184e00f7, moduleTitle=Blood：NPM1/FLT3-ITD分型对AML患者预后的预测意义, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=54ec184e00f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538891, encodeId=fa8615388912c, content=<a href='/topic/show?id=5f04e51467' target=_blank style='color:#2F92EE;'>#FLT3#</a>, objectTitle=NEJM:Gilteritinib治疗FLT3突变型AML, objectType=article, longId=182253, objectId=6aab18225341, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6aab18225341, replyNumber=0, likeNumber=23, createdTime=2019-11-03, rootId=0, userName=fengyi816, userId=57a713069145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6aab18225341, moduleTitle=NEJM:Gilteritinib治疗FLT3突变型AML, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6aab18225341)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538890, encodeId=f9fb1538890c2, content=<a href='/topic/show?id=5f04e51467' target=_blank style='color:#2F92EE;'>#FLT3#</a>, objectTitle=Blood：TdT通过启动FLT3-ITD复制滑移促进AML, objectType=article, longId=181712, objectId=8814181e1279, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8814181e1279, replyNumber=0, likeNumber=35, createdTime=2019-10-23, rootId=0, userName=fengyi816, userId=57a713069145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8814181e1279, moduleTitle=Blood：TdT通过启动FLT3-ITD复制滑移促进AML, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8814181e1279)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538889, encodeId=957515388890f, content=<a href='/topic/show?id=5f04e51467' target=_blank style='color:#2F92EE;'>#FLT3#</a>, objectTitle=CHMP对FLT3抑制剂Quizardinib治疗复发/难治性AML患者持负面意见, objectType=article, longId=181643, objectId=849918164324, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=849918164324, replyNumber=0, likeNumber=36, createdTime=2019-10-21, rootId=0, userName=fengyi816, userId=57a713069145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=849918164324, moduleTitle=CHMP对FLT3抑制剂Quizardinib治疗复发/难治性AML患者持负面意见, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=849918164324)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538888, encodeId=6150153888870, content=<a href='/topic/show?id=5f04e51467' target=_blank style='color:#2F92EE;'>#FLT3#</a>, objectTitle=Blood：靶向PRMT1介导的FLT3甲基化有望打破MLL重排型ALL的持续存在, objectType=article, longId=177372, objectId=36981e7372b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36981e7372b1, replyNumber=0, likeNumber=0, createdTime=2019-08-11, rootId=0, userName=fengyi816, userId=57a713069145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36981e7372b1, moduleTitle=Blood：靶向PRMT1介导的FLT3甲基化有望打破MLL重排型ALL的持续存在, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36981e7372b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

FLT3

2020-05-29

fengyi816 (审核中...)

前往app查看评论内容

#FLT3#

Blood：Gilteritinib联合阿扎胞苷 vs 单用阿扎胞苷治疗新诊断的FLT3mut+AML

2022-08-12

fengyi816 (审核中...)

前往app查看评论内容

#FLT3#

《BLOOD》吉瑞替尼联合阿扎胞苷治疗不适合强化疗的初治FLT3突变AML的3期研究结果

2022-08-11

fengyi816 (审核中...)

前往app查看评论内容

#FLT3#

J Clin Oncol：维奈托克联合吉特替尼治疗FLT3突变型急性髓系白血病

2022-08-03

fengyi816 (审核中...)

前往app查看评论内容

#FLT3#

Ann Hematol：吉列替尼单药治疗复发/难治性 FLT3 突变急性髓细胞白血病的真实世界研究

2022-06-30

fengyi816 (审核中...)

前往app查看评论内容

#FLT3#

J Clin Oncol：索拉非尼联合标准化疗治疗FLT3/ITD+急性髓系白血病患儿的疗效和安全性

2022-04-14

fengyi816 (审核中...)

前往app查看评论内容

#FLT3#

Blood：FLT3抑制剂Gilteritinib vs 挽救化疗对复发/难治性AML患者长期预后的影响

2022-02-28

fengyi816 (审核中...)

前往app查看评论内容

#FLT3#

Blood：急性髓系白血病FLT3-ITD突变的克隆进化

2021-06-13

fengyi816 (审核中...)

前往app查看评论内容

#FLT3#

Blood：靶向PRMT1介导的FLT3甲基化可增强MLL重排的ALL细胞的清除

2021-06-12

fengyi816 (审核中...)

前往app查看评论内容

#FLT3#

靶向治疗新时代！吉瑞替尼成为全国最佳治疗FLT3突变型AML靶向药

2021-05-02

fengyi816 (审核中...)

前往app查看评论内容

#FLT3#

Blood：糖皮质激素可增强FLT3抑制剂的抗FLT3突变型AML活性

2020-08-12

fengyi816 (审核中...)

前往app查看评论内容

#FLT3#

FLT3抑制剂gilteritinib，获得英国NICE推荐治疗急性髓性白血病

2020-07-20

fengyi816 (审核中...)

前往app查看评论内容

#FLT3#

Blood：NPM1突变/MLL重排白血病患者的新希望：联合抑制Menin-MLL和FLT3

2020-07-05

fengyi816 (审核中...)

前往app查看评论内容

#FLT3#

Blood：糖皮质激素增强了FLT3抑制剂的抗FLT3突变型AML活性

2020-06-05

fengyi816 (审核中...)

前往app查看评论内容

#FLT3#

Astellas宣布其FLT3抑制剂XOSPATA治疗白血病，正在NMPA接受监管审查

2020-04-13

fengyi816 (审核中...)

前往app查看评论内容

#FLT3#

Blood：FLT3抑制上调HDAC8使p53失活，维持FLT3-ITD+ AML细胞存活

2020-02-16

fengyi816 (审核中...)

前往app查看评论内容

#FLT3#

Blood：NPM1/FLT3-ITD分型对AML患者预后的预测意义

2019-12-14

fengyi816 (审核中...)

前往app查看评论内容

#FLT3#

NEJM:Gilteritinib治疗FLT3突变型AML

2019-11-03

fengyi816 (审核中...)

前往app查看评论内容

#FLT3#

Blood：TdT通过启动FLT3-ITD复制滑移促进AML

2019-10-23

fengyi816 (审核中...)

前往app查看评论内容

#FLT3#

CHMP对FLT3抑制剂Quizardinib治疗复发/难治性AML患者持负面意见

2019-10-21

fengyi816 (审核中...)

前往app查看评论内容

#FLT3#

Blood：靶向PRMT1介导的FLT3甲基化有望打破MLL重排型ALL的持续存在

2019-08-11

科室
- - 订阅+
  - 更多科室
工具
服务